

A Euronext Company

Une filiale d'Euronext

Genticel lists on Euronext in Paris and Brussels

Brussels, Paris – 4 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs¹, congratulates today Genticel, a French biotechnology company and specialist in the development of therapeutic vaccines whose objectives are to eliminate the human papillomavirus (HPV) responsible for cervical cancer, on its successful admission to trading on Euronext's compartment C in Paris and in Brussels.

Based in Paris and Toulouse, Genticel develops therapeutic vaccines against cervical cancer. Its therapeutic vaccine candidates are aimed at eliminating, at an early stage, cells carrying the human papillomavirus (HPV) responsible for cervical cancer, one of the most common cancers of women worldwide. ProCervix, a "first-in-class" therapeutic vaccine candidate currently in Phase II clinical trials, is designed to eliminate cells infected by type 16 and/or type 18 HPV virus located at the cervix of the uterus before the development of high-grade or cancerous lesions, thus addressing a serious public health problem. Genticel is also developing a second therapeutic vaccine candidate called Multivalent HPV that targets six strains of cancerous HPV.

Genticel (ticker symbol: GTCL) was listed through the admission to trading of its existing shares making up the company's equity and the 4,367,088 newly issued shares related to the €34,5 million capital increase.

The admission and issue price of Genticel shares was set at €7.90 per share leading to a market capitalisation of approximately €119.4 million.

"We congratulate Genticel on its dual listing in Paris and Brussels. This IPO will help the company raise its liquidity and visibility with investor community, both domestic and international," said Eric Forest, Chairman and CEO of EnterNext. *"Enternext will be advising and assisting Genticel at each stage in its growth and participation in trading, in particular to help it make best use of the range of financing solutions available to it on our markets."*

Benedikt Timmerman, Genticel founder and CEO, said: *"We are delighted with the interest investors showed in our company and our successful IPO. We strongly thank all the investors that have joined us at this occasion as well as our historic shareholders who renewed their confidence in our company as we*

¹ Small and medium-sized enterprises

reach this important milestone in GenticeL's growth. . We are also very pleased with the interest shown by individual investors, particularly in Belgium and have therefore taken extra measures to better meet their demand for stock. We now have the financial resources that we need to develop our portfolio of candidate therapeutic vaccines, which are designed to give therapeutic options to women carrying the human papillomavirus and hereby reduce the number of cases of cervix carcinoma. In particular, GenticeL will continue developing ProCervix, our lead candidate, which has blockbuster potential, with a view of forging a value creating industrial partnership in the nearby years ahead."

CONTACTS

Euronext:

Caroline Tourrier (Paris): +33 1 49 27 10 82

ctourrier@nyx.com

GenticeL / Actus Finance et Communication:

Press:

Alexandra Prisa

+33 1 53 67 35 79; aprisa@actus.fr

Investor relations:

Corinne Puissant

Edouard de Maissin

+33 01 53 67 35 71; genticel@actus.fr

About GenticeL

GenticeL is a French pharmaceutical company specialising in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.

GenticeL is developing the first-ever therapeutic vaccine, currently in Phase II clinical trials, aimed at eliminating cells infected by type 16 and/or 18 HPV virus located at the cervix of the uterus. A second therapeutic vaccine candidate targeting six of the most pertinent strains of HPV is currently in preclinical stage. Over many years of R&D, the company has also produced Vaxiclose, a technology platform ideally adapted for developing early-intervention immunotherapies against multiple infectious or cancerous diseases.

Based in Paris and Toulouse, GenticeL was awarded the 2013 Innovation Prize by the Grands Prix de l'Economie.

For more information, visit www.genticel-bourse.com

About EnterNext

Launched in May 2013, EnterNext is the subsidiary of the Euronext Group designed to develop and promote its stock markets specifically for small and medium-size enterprises (SMEs). Drawing on its pan-European presence, EnterNext brings together all Euronext Group initiatives for companies with market capitalisations under €1 billion, including companies listed in the B and C compartments of its regulated European markets and on Alternext, the market tailored to the needs of SMEs. EnterNext plays an active role in facilitating SMEs' access to financial markets, helping them generate the funds they need to grow at regional, national and pan-European level. Euronext is a wholly owned subsidiary of IntercontinentalExchange Group (ICE).

About

Euronext

Euronext is the primary exchange in the Euro zone with over 1,300 issuers worth €2.6 trillion in market capitalization, an unmatched blue chip franchise consisting of 20+ issuers in the EURO STOXX 50® benchmark, and a strong diverse domestic and international client base.

Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its

expertise of running markets by providing technology and managed services to third parties. Euronext operates regulated markets, Alternext and the Free Market; in addition it offers EnterNext, which facilitates SMEs' access to capital markets. Euronext is a wholly owned subsidiary of IntercontinentalExchange Group (ICE).

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 - Statements in this press release regarding ICE's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE's Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE's Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC on February 14, 2014.